<DOC>
	<DOCNO>NCT01997203</DOCNO>
	<brief_summary>Treatment hepatitis C virus ( HCV ) infection carry use pegylated interferon ( PEG-IFN ) , ribavirin ( RBV ) vitamin D ( vit D ) 48 week HCV genotypes 4a subject . The purpose study determine effect vitamin D liver affection patient .</brief_summary>
	<brief_title>Long Term Vitamin D Therapy HCV Treated Patients</brief_title>
	<detailed_description>Fifty patient study group administer vit D compare 50 patient control group without vit D. The result show significant elevation vit D level time period , significant reduction HCV RNA 12th wk reach zero level 24th wk . Interleukin 6 ( IL-6 ) , visfatin hyaluronic acid level reduce significantly reach normal value . These concentration reduction effect vit D HCV indicate reduction inflammation , infection liver cirrhosis nearly amelioration HCV .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>Chronic HCV infection ( positive HCV Ab 6 month ) Treated pegylated interferon ribavirin Coinfection Hepatitis B Hepatitis D Human Immunodeficiency Virus Previous non response antiviral therapy . Other cause chronic liver disease schistosomiasis , Wilson disease alcoholic liver disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>hepatitis C infection</keyword>
	<keyword>vitamin D</keyword>
</DOC>